|
🐜
|
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
11 auth.
J. Colombel,
W. Sandborn,
P. Rutgeerts,
R. Enns,
S. Hanauer,
R. Panaccione,
...
S. Schreiber,
Daniel Byczkowski,
Ju Li,
J. Kent,
P. Pollack
|
11 |
2007 |
11
🐜
|
|
🐜
|
A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end‐stage renal disease
12 auth.
B. G. Abu Jawdeh,
E. Woodle,
A. Leino,
P. Brailey,
S. Tremblay,
Tonya Dorst,,
...
Mouhamad H Abdallah,
A. Govil,
Daniel Byczkowski,
H. Misra,
A. Abuchowski,
R. Alloway
|
3 |
2018 |
3
🐜
|
|
🐜
|
ANF-Rho: A Dose-Ranging Phase I Study to Determine Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
8 auth.
D. Parmar,
Daniel Byczkowski,
R. Jubin,
A. Abuchowski,
P. Buontempo,
G. Gitlin,
...
Michelle Boro,
H. Misra
|
0 |
2015 |
0
🐜
|
|
🐬
|
Phase I pharmacokinetic and pharmacodynamic results of novel anti-neutropenic factor for the prevention and treatment of febrile neutropenia.
R. Jubin,
P. Buontempo,
Daniel Byczkowski,
H. Misra,
A. Abuchowski
|
0 |
2016 |
0
🐬
|
